KCA-1490

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 562049

CAS#: 909719-71-7

Description: KCA-1490 is a dual PDE3/4 inhibitor.

Chemical Structure

img
KCA-1490
CAS# 909719-71-7
Instruction

Theoretical Analysis

MedKoo Cat#: 562049
Name: KCA-1490
CAS#: 909719-71-7
Chemical Formula: C14H13F3N4O2
Exact Mass: 326.10
Molecular Weight: 326.270
Elemental Analysis: C, 51.54; H, 4.02; F, 17.47; N, 17.17; O, 9.81

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Synonym: KCA-1490; KCA 1490; KCA1490;

IUPAC/Chemical Name: 6-(7-Methoxy-2-trifluoromethylpyrazolo[1,5-a]pyridin-4-yl)-5-methyl-4,5-dihydro-2H-pyridazin-3-one

InChi Key: IDPCPRHAKGSESY-UHFFFAOYSA-N

InChi Code: InChI=1S/C14H13F3N4O2/c1-7-5-11(22)18-19-13(7)8-3-4-12(23-2)21-9(8)6-10(20-21)14(15,16)17/h3-4,6-7H,5H2,1-2H3,(H,18,22)

SMILES Code: O=C1CC(C)C(C2=CC=C(OC)N3C2=CC(C(F)(F)F)=N3)=NN1

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 326.27 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Kojima A, Takita S, Sumiya T, Ochiai K, Iwase K, Kishi T, Ohinata A, Yageta Y, Yasue T, Kohno Y. Phosphodiesterase inhibitors. Part 6: design, synthesis, and structure-activity relationships of PDE4-inhibitory pyrazolo[1,5-a]pyridines with anti-inflammatory activity. Bioorg Med Chem Lett. 2013 Oct 1;23(19):5311-6. doi: 10.1016/j.bmcl.2013.07.069. Epub 2013 Aug 8. PubMed PMID: 23988356.

2: Ochiai K, Takita S, Kojima A, Eiraku T, Iwase K, Kishi T, Ohinata A, Yageta Y, Yasue T, Adams DR, Kohno Y. Phosphodiesterase inhibitors. Part 5: hybrid PDE3/4 inhibitors as dual bronchorelaxant/anti-inflammatory agents for inhaled administration. Bioorg Med Chem Lett. 2013 Jan 1;23(1):375-81. doi: 10.1016/j.bmcl.2012.08.121. Epub 2012 Nov 9. PubMed PMID: 23200255.

3: Ochiai K, Takita S, Kojima A, Eiraku T, Ando N, Iwase K, Kishi T, Ohinata A, Yageta Y, Yasue T, Adams DR, Kohno Y. Phosphodiesterase inhibitors. Part 4: design, synthesis and structure-activity relationships of dual PDE3/4-inhibitory fused bicyclic heteroaromatic-4,4-dimethylpyrazolones. Bioorg Med Chem Lett. 2012 Sep 15;22(18):5833-8. doi: 10.1016/j.bmcl.2012.07.088. Epub 2012 Jul 31. PubMed PMID: 22884989.

4: Ochiai K, Takita S, Eiraku T, Kojima A, Iwase K, Kishi T, Fukuchi K, Yasue T, Adams DR, Allcock RW, Jiang Z, Kohno Y. Phosphodiesterase inhibitors. Part 3: Design, synthesis and structure-activity relationships of dual PDE3/4-inhibitory fused bicyclic heteroaromatic-dihydropyridazinones with anti-inflammatory and bronchodilatory activity. Bioorg Med Chem. 2012 Mar 1;20(5):1644-58. doi: 10.1016/j.bmc.2012.01.033. Epub 2012 Jan 28. PubMed PMID: 22336247.

5: Ochiai K, Ando N, Iwase K, Kishi T, Fukuchi K, Ohinata A, Zushi H, Yasue T, Adams DR, Kohno Y. Phosphodiesterase inhibitors. Part 2: design, synthesis, and structure-activity relationships of dual PDE3/4-inhibitory pyrazolo[1,5-a]pyridines with anti-inflammatory and bronchodilatory activity. Bioorg Med Chem Lett. 2011 Sep 15;21(18):5451-6. doi: 10.1016/j.bmcl.2011.06.118. Epub 2011 Jul 2. PubMed PMID: 21764304.